# EDGAR Filing Document

**Accession Number:** 0001232258
**File Stem:** 0001104659-23-017791
**Filing Date:** 2023-2
**Character Count:** 5485
**Document Hash:** 3631aaebb2ce328d81e37ae14a6810b8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-017791.hdr.sgml**: 20230209

**ACCESSION NUMBER**: 0001104659-23-017791

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230209

**FILED AS OF DATE**: 20230209

**DATE AS OF CHANGE**: 20230209

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** HBM Healthcare Investments (Cayman) Ltd.
- **CENTRAL INDEX KEY:** 0001232258
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41614
- **FILM NUMBER:** 23608252

**BUSINESS ADDRESS:**
- **STREET 1:** GOVERNORS SQUARE, 23 LIME TREE BAY AVE.,
- **STREET 2:** PO BOX 30852
- **CITY:** GRAND CAYMAN
- **STATE:** E9
- **ZIP:** KY1-1204
- **BUSINESS PHONE:** 345-946-8002

**MAIL ADDRESS:**
- **STREET 1:** GOVERNORS SQUARE, 23 LIME TREE BAY AVE.,
- **STREET 2:** PO BOX 30852
- **CITY:** GRAND CAYMAN
- **STATE:** E9
- **ZIP:** KY1-1204

**FORMER NAME:**
- **FORMER CONFORMED NAME:** HBM BIOVENTURES CAYMAN LTD
- **DATE OF NAME CHANGE:** 20030512
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Mineralys Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001933414
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 150 N. RADNOR CHESTER ROAD
- **STREET 2:** SUITE F200
- **CITY:** RADNOR
- **STATE:** PA
- **ZIP:** 19087
- **BUSINESS PHONE:** (888) 378-6240

**MAIL ADDRESS:**
- **STREET 1:** 150 N. RADNOR CHESTER ROAD
- **STREET 2:** SUITE F200
- **CITY:** RADNOR
- **STATE:** PA
- **ZIP:** 19087

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>HBM Healthcare Investments (Cayman) Ltd.<br><sub>(Last) (First) (Middle)</sub><br>GOVERNORS SQUARE, SUITE #4-212-2<br>23 LIME TREE BAY AVE., WEST BAY<br><sub>(Street)</sub><br>GRAND CAYMAN, E9 00000<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Mineralys Therapeutics, Inc. [ MLYS ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2023-02-09 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Series A Preferred Stock | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 1941368 | <sup>(1)</sup> | D |  |
| Series B Preferred Stock | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 964238 | <sup>(2)</sup> | D |  |

---

### Footnotes:

(1) Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series A  Preferred Stock beneficially owned by the reporting person will automatically convert, for no additional consideration, into the number of shares of Common Stock reported in Column 3. These shares of Series A  Preferred Stock have no expiration date.

(2) Upon the closing of the Issuer's IPO, each share of Series B  Preferred Stock beneficially owned by the reporting person will automatically convert, for no additional consideration, into the number of shares of Common Stock reported in Column 3. These shares of Series B  Preferred Stock have no expiration date.

**Signature:** /s/ Jean-Marc LeSieur, Managing Director  
**Date:** 2023-02-09

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**